Andrew R. Boll
2020
In 2020, Andrew R. Boll earned a total compensation of $1M as Chief Financial Officer at Imprimis Pharmaceuticals, a 3% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $153,066 |
|---|---|
| Option Awards | $248,520 |
| Salary | $409,655 |
| Stock Awards | $193,325 |
| Other | $12,238 |
| Total | $1,016,804 |
Boll received $409.7K in salary, accounting for 40% of the total pay in 2020.
Boll also received $153.1K in non-equity incentive plan, $248.5K in option awards, $193.3K in stock awards and $12.2K in other compensation.
Rankings
In 2020, Andrew R. Boll's compensation ranked 8,564th out of 13,090 executives tracked by ExecPay. In other words, Boll earned more than 34.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,564 out of 13,090 | 35th |
Division Manufacturing | 3,645 out of 5,618 | 35th |
Major group Chemicals And Allied Products | 1,473 out of 2,251 | 35th |
Industry group Drugs | 1,282 out of 1,951 | 34th |
Industry Pharmaceutical Preparations | 947 out of 1,456 | 35th |
Source: SEC filing on April 23, 2021.
Boll's colleagues
We found two more compensation records of executives who worked with Andrew R. Boll at Imprimis Pharmaceuticals in 2020.
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019